October 4, 2010 -- ShangPharma Corp., the Shanghai-based CRO, announced plans to stage a $90 million IPO on the New York Stock Exchange. Founded in 2003, the company is one of the largest CROs in China with a staff of more than 1,600 scientists. One of its six divisions, Shanghai ChemPartner, is devoted exclusively to projects from Eli Lilly Company. More details....
